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The p53 tumor suppressor regulates diverse antiproliferative pro-
cesses such that cells acquiring p53 mutations have impaired
cell-cycle checkpoints, senescence, apoptosis, and genomic stabil-
ity. Here, we use stable RNA interference to examine the role of
PUMA, a p53 target gene and proapoptotic member of the Bcl2
family, in p53-mediated tumor suppression. PUMA short hairpin
RNAs (shRNAs) efficiently suppressed PUMA expression and p53-
dependent apoptosis but did not impair nonapoptotic functions of
p53. Like p53 shRNAs, PUMA shRNAs promoted oncogenic trans-
formation of primary murine fibroblasts by the E1Aras oncogene
combination and dramatically accelerated myc-induced lym-
phomagenesis without disrupting p53-dependent cell-cycle arrest.
However, the ability of PUMA to execute p53 tumor suppressor
functions was variable because, in contrast to p53 shRNAs, PUMA
shRNAs were unable to cooperate with oncogenic ras in transfor-
mation. These results demonstrate that the p53 effector functions
involved in tumor suppression are context dependent and, in some
settings, depend heavily on the expression of a single proapoptotic
effector. Additionally, they demonstrate the utility of RNA inter-
ference for evaluating putative tumor suppressor genes in vivo.
The p53 tumor suppressor is a transcription factor that con-trols diverse cellular processes such as DNA repair, cell-cycle
checkpoints, senescence, apoptosis, and angiogenesis (1). In
principle, disruption of each of these activities alone or in
combination could explain the potent impact of p53 mutations
on tumorigenesis. Attempts to identify relevant p53 activities
have used mouse models or cells derived from these animals to
determine whether disruption of individual p53 effectors can
mimic p53 loss during tumorigenesis. To date, the biological
consequences of inactivating these effectors have not been as
severe as those obtained by inactivating p53 itself. For example,
disruption of either bax (an apoptotic regulator) or p21 (a
proliferation inhibitor) does not recapitulate p53 loss in promot-
ing transformation or tumorigenesis (2–4). Although these
observations suggest that disruption of multiple p53 functions
is required to support tumorigenesis, it is also clear that
p53 coordinates each activity through multiple effectors whose
single inactivation is not sufficient to completely disable each
activity (5).
Other studies have taken a more global approach to specifi-
cally target p53 activities, albeit with apparently contradictory
results. For example, during myc-induced B cell lymphomagen-
esis, coexpression of bcl2, which completely disables apoptosis
downstream of p53, mimics p53 mutations in producing aggres-
sive malignancies that retain p53-dependent cell-cycle check-
points (6). Although these results suggest that apoptosis is the
primary p53 activity responsible for tumor suppression in this
model, p53 deficiency, but not expression of bcl2, is efficient at
promoting T cell lymphomagenesis (7–9). Furthermore, mice
harboring p53 point mutants that are incapable of transactivating
p53 proapoptotic targets fail to develop the T cell lymphomas
characteristic of p53-null mice (7, 10). In the latter setting,
genomic instability, and not apoptosis, was proposed to explain
the advantage of p53 mutations during tumorigenesis.
PUMA (p53 up-regulated modulator of apoptosis) is a ‘‘BH3-
only’’ member of the Bcl2 family that was initially identified from
differential gene expression studies as a p53 target gene and a
potent inducer of apoptosis (11, 12). PUMA acts by modulating
Bax activity to facilitate cytochrome c release from the mito-
chondria, thereby triggering the apoptotic cascade (11). PUMA-
deficient colon carcinoma cells and MEFs derived from PUMA-
deficient mice are resistant to several apoptotic stimuli, including
those acting through p53 (13, 14). In fact, the similar phenotypes
of PUMA/ and p53/ cells suggest that PUMA is an essential
p53 effector during apoptosis under some conditions. However,
PUMA/ mice are not overtly tumor-prone, again suggesting
that simultaneous inactivation of multiple p53 effector functions
is critical for tumorigenesis (15).
We have proposed that not all p53 effector functions contrib-
ute to tumor suppression, and, instead, that loss of specific p53
activities can play crucial roles that are context-dependent (6,
16). For example, whereas apoptosis appears to be the primary
p53 activity limiting myc-induced lymphomagenesis, both apo-
ptosis and cellular senescence contribute to chemotherapy re-
sponsiveness (6, 17). Because PUMA can be a specific and
essential mediator of p53-dependent apoptosis, the impact of
PUMA loss on malignant phenotypes should reveal the relative
contribution of apoptosis to p53-mediated tumor suppression in
different contexts. Therefore, we used stable RNA interference
(RNAi) to acutely suppress PUMA expression in settings where
p53 has established tumor-suppressor activity. In contrast to
studies with traditional knockout mice, studies with RNAi
exploit short hairpin RNAs (shRNAs) to acutely and stably
suppress gene expression, providing an extremely rapid ap-
proach to study loss-of-function effects in vitro and in vivo (16,
18). Also, RNAi can produce hypomorphic expression states that
may more closely mimic basal expression states or the activity of
a mutated gene than a null allele. Here, we use this approach to
identify PUMA as a potential tumor suppressor and highlight
important features of the p53 tumor-suppressor network.
Materials and Methods
Cells and Gene Transfer. Primary murine embryonic fibroblasts
were derived from WT and p53/ day 13.5 embryos and
maintained as described in refs. 19 and 20. Retroviruses encod-
ing shRNAs expressed from the U6 promoter were generated by
PCR with a pGEM U6 promoter template (16). The shRNA
sequences encoded inverted repeats of 29 nt separated by an 8-nt
spacer. The inverted repeats corresponded to nucleotides 772–
802 (shPU-2) or 500–528 (shPU-3) of the mouse PUMA cDNA
(NM133234) and had 3-nt differences compared with any
other murine genes as determined by BLAST. The shp53 sequence
used was the same as the ‘‘p53.2’’ published in ref. 16. The
resulting PCR products were cloned directly into the HpaI site
of the murine stem cell virus (MSCV) phosphoglycerate kinase
(PGK)-Puro-internal ribosome entry site (IRES)-GFP vector
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(16) or, for the p53 shRNA vector used in vitro, pQCXIX
PGK-Puro-IRES-GFP (modified from Clontech’s pQCXIX).
The exact primer sequences and cloning strategies are available
from the authors upon request. All animal protocols were
approved by Cold Spring Harbor Laboratory in accordance with
National Institutes of Health guidelines.
Retroviral-mediated gene transfer was performed by using
Phoenix packaging cells (G. Nolan, Stanford University, Stan-
ford, CA) as described in ref. 20. Oncogenic ras (H-RasV12) (20)
and E1A were expressed by using WZL-Hygro-based retroviral
vectors (Ariad Pharmaceuticals, Cambridge, MA). E1AH-
RasV12 was expressed by using a modified pBabe H-RasV12
retroviral vector (20). Infected cell populations were selected by
culture in puromycin (2 gml, 3 days) or hygromycin (100
gml, 3 days) to eliminate uninfected cells.
PUMA Suppression and Functional Assays. Cells were extracted in
RIPA buffer (50 mM Tris, pH 7.4150 mM NaCl1% Triton
X-100, 0.1% SDS1% sodium deoxycholate) supplemented with
Complete Mini protease inhibitors (Roche Diagnostics). We
assessed protein expression by immunoblotting as described in
ref. 21, with primary antibodies directed against PUMA (1:300)
from ProSci (San Diego), p53 (1:500) from NovoCastra (New-
castle, U.K.), or -tubulin (1:4,000) from Sigma. Mouse embryo
fibroblasts (MEFs) used in E1Aras death assays were plated
into 12-well plates (105 cells per well) in medium containing
either 10% or 0.1% FBS and incubated for 36 h. Cell viability
was analyzed by trypan blue exclusion, and at least 200 cells were
scored for each sample.
For BrdUrd incorporation assays, 1  105 p53/ MEFs or
WT MEFs infected with MSCV control, shPU-3, or shp53
viruses were plated in triplicate on sterile coverslips in six-well
dishes. Twelve hours after plating, MEFs were exposed to 6-Gy
-radiation. Fourteen hours later, cells were pulsed with
BrdUrd for 4 h. BrdUrd incorporation and colony formation
assays were performed as described in ref. 16. For lymphoma
DNA damage checkpoint analysis, tumor-bearing mice were
either irradiated at 6 Gy or left untreated. Thirty-six hours
later, lymphoma cells were harvested from irradiated and
control mice, fixed in 70% ethanol, and stained with propidium
iodide for cell-cycle analysis (6).
Tumorigenicity Assays. For tumorigenicity assays, 1 106 cells per
0.25 ml of PBS were injected s.c. into NIH Swiss athymic nude
mice (Taconic Farms) and monitored as described in ref. 22.
MEFs from two different embryo preparations were infected
with retroviruses containing shRNAs targeting PUMA or p53 in
the presence of MSCV vector, ras, or E1Aras. Isolation, infec-
tion, and transplantation of hematopoietic stem cells derived
from embryonic day 15 WT or E-myc was performed as
described in ref. 6. Reconstituted animals were monitored for
illness by lymph node palpation, by monitoring overall morbid-
ity, and, in some cases, by whole-body fluorescence imaging (8).
Overall survival was defined as the time from stem cell recon-
stitution until the animal reached a terminal stage and was killed.
In all cases, terminal animals harbored large tumor burdens.
Statistical analysis was performed with a one-way ANOVA test
by using PRISM (Version 3.0, GraphPad, San Diego).
Immunophenotyping was performed on three shPUMA and
three shp53-induced lymphomas. Briefly, 1  106 freshly har-
vested lymphoma cells were washed two times in PBS with 2%
FBS. Cells were then incubated for 1 h in 200 l of PBS with 10%
FBS containing 1:100 dilutions of phycoerythrin-conjugated
B220, Thy1, and IgM (Pharmingen). After incubation with
surface antibodies, cells were washed two times in PBS with 2%
FBS. Flow cytometry analysis was performed on a Becton
Dickinson LSRII cell analyzer equipped with FACSVANTAGE
DIVA software.
Results
PUMA shRNAs Can Suppress PUMA Levels and Activity. MEFs ex-
pressing E1A or myc become sensitized to apoptosis after DNA
damage or serum depletion (5). In contrast, oncogene-
expressing MEFs derived from both p53/ and PUMA/ mice
are resistant to apoptosis (14–15, 23), suggesting that PUMA is
essential for p53-mediated cell death in this context. To deter-
mine whether suppression of PUMA by using RNAi could be
effective, we generated PUMA shRNAs against distinct se-
quences in the PUMA gene (designated shPU-2 and shPU-3),
cloned them into a retroviral expression vector, and tested their
activity after introduction into MEFs. PUMA shRNAs were
capable of efficiently suppressing PUMA expression, even in
E1Aras-expressing cells that harbor stabilized p53 (Fig. 1A)
(data not shown). Furthermore, like a p53 shRNA, PUMA
shRNAs protected E1Aras-expressing MEFs against apoptosis
after serum depletion (Fig. 1B). Therefore, PUMA shRNAs are
capable of modulating PUMA expression and activity.
PUMA Suppression Does Not Affect p53-Dependent Cell-Cycle Arrest.
p53 is essential for cell-cycle arrest after DNA damage (24). To
rule out the possibility that PUMA affects p53 arrest functions,
we examined the ability of MEFs expressing PUMA or p53
shRNAs to undergo cell-cycle arrest after -irradiation. Both
vector control and shPUMA-expressing MEFs retained an intact
Fig. 1. Analysis of PUMA shRNA function in vitro. (A) Western blot analysis
showing p53 and PUMA levels in E1Aras MEFs stably expressing an MSCV
control vector or PUMA and p53 shRNAs. Tubulin is shown as a loading control.
(B) E1Aras MEFs transduced with an MSCV control vector or p53 and PUMA
shRNAs were incubated in highlow serum for 36 h after which viability was
assessed by trypan blue exclusion.
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DNA damage checkpoint after irradiation, as indicated by an
5-fold decrease in BrdUrd relative to unirradiated controls
(Fig. 2 A and B). In contrast, shp53-expressing MEFs and
p53-null MEFs showed no significant reduction in BrdUrd
incorporation after -irradiation (Fig. 2 A and B).
WT MEFs undergo senescence when plated at clonogenic
density, whereas p53-deficient MEFs form colonies that are
readily immortalized (19). To determine whether PUMA could
influence the ability of p53 to promote senescence, MEFs
expressing shRNAs targeting PUMA or p53 were plated at low
density and examined for colony formation after 2 weeks. In
agreement with the acute arrest assays, PUMA shRNAs had no
impact on colony formation, whereas p53 shRNAs were highly
effective (Fig. 2C). In this assay, p53-deficiency and p53 shRNAs
resulted in the significant enhancement of the ability of untrans-
formed cells to form colonies when plated at clonogenic density
(Fig. 2C). Therefore, although suppression of PUMA can effec-
tively disable p53 apoptotic functions, it has no impact on
p53-mediated cell-cycle arrest.
PUMA Can Be a Potent Suppressor of Transformation. p53 tumor
suppressor activity has been extensively studied in primary
rodent cells, where p53 mutations can cooperate with the
combination of E1A and ras oncogenes, or oncogenic ras alone,
in promoting oncogenic transformation (19, 25, 26). To deter-
mine the extent to which PUMA suppression could mimic p53
mutations in these assays, we introduced shRNAs targeting
PUMA or p53 into WT or p53/ MEFs, along with retroviruses
that coexpressed E1Aras or ras alone. After transduction, the
infected cell populations were injected s.c. into immunocom-
promised mice, which were monitored for tumor formation at
the sites of injection. Because the PUMA and p53 shRNAs also
coexpressed a GFP reporter, tumor formation also could be
visualized by whole-body fluorescence imaging.
PUMA shRNAs acted as potent inducers of transformation in
cells coexpressing E1Aras, because the transduced cell popu-
lations appeared morphologically transformed (data not shown)
and formed rapidly progressing tumors at the majority of
injected sites (Fig. 3). Indeed, the ability of PUMA shRNAs to
enhance the tumorigenicity of E1Aras MEFs was similar to that
produced by a p53 shRNA (Fig. 3A), although the tumors
progressed at a somewhat slower rate (Fig. 3B). Importantly, no
tumors occurred in E1Aras MEFs infected with the control
vector. Furthermore, both PUMA shRNAs tested were effective
in this assay, indicating that their oncogenic effects were unlikely
to result from off-target oncogenic activities. Therefore, PUMA
can approximate p53 action in suppressing transformation by
E1A and ras.
The same transforming effects of PUMA shRNAs were not
observed in the presence of oncogenic ras alone. Hence, cell
populations expressing PUMA shRNAs and ras appeared mor-
phologically senescent (data not shown) and, like cells coex-
pressing ras and the control vector, did not form tumors at any
of the injected sites (Fig. 3 A and C). These observations are in
stark contrast to WT MEFs expressing a p53 shRNA or p53-
deficient MEFs, where oncogenic ras was highly tumorigenic.
Therefore, PUMA suppression can approximate p53 loss in
promoting transformation by some oncogene combinations, but
not others. Because both the E1Aras and ras transformation
assays were performed in the same MEF populations, these
differences must reflect a distinct requirement for p53 effectors
in different signaling environments.
PUMA Loss Accelerates E-myc Lymphomagenesis. E-myc trans-
genic mice express the c-myc oncogene from an Ig heavy chain
Fig. 2. PUMA suppression does not impair p53-mediated cell-cycle arrest. (A) Representative fields of a BrdUrd-incorporation assay showing the response of
p53 and PUMA shRNA-expressing MEFs to ionizing radiation. (B) Quantitation of the data in A, including MSCV control-infected and p53/ MEFs. The relative
ratios of BrdUrd incorporation for irradiated vs. nonirradiated cells are shown. (C) A colony-formation assay performed on p53/ MEFs and WT MEFs infected
with MSCV control (vector), shPU-3, and shp53. In each well, 2,500 cells were plated and cultured for 12 days before staining with crystal violet.






enhancer and develop B cell lymphomas between 3 and 6 months
of age (27). However, E-myc lymphomas harboring p53 dele-
tions arise much more rapidly and typically display a more
aggressive and disseminated pathology (28). Hematopoietic
stem cells (HSCs) from E-myc transgenic mice also give rise to
lymphomas upon adoptive transfer into normal recipients, and
these lymphomas can be greatly accelerated by p53 suppression
by RNAi (16). Given the ability of PUMA to mediate p53-
dependent apoptotic activity in MEFs, we investigated whether
stable suppression of PUMA in E-myc hematopoietic stem cells
by RNAi could recapitulate the effects of p53 deletions and
accelerate lymphomagenesis in recipient animals.
HSCs derived from E-myc fetal livers were infected with
retroviruses encoding a control vector, shPU-2, shPU-3, or a p53
shRNA, and the resulting populations were used to reconstitute
the hematopoietic system of lethally irradiated mice. Whereas
only 40% of mice reconstituted with control HSCs developed
lymphomas (four of 10, average survival of 120 29 days), 100%
of the mice receiving shPUMA-expressing HSCs developed
lymphomas with dramatically reduced latency (n  12, average
survival 49 7 and 59 4 for shPU-2 and shPU-3, respectively;
P  0.001 relative to controls). Importantly, lymphomas arising
from shPUMA-transduced shRNAs contained the shPUMA
retrovirus and suppressed PUMA protein because all 12 of these
lymphomas were GFP-positive (compared to only 1 of 4 con-
trols) and showed substantially reduced PUMA expression
relative to E1Aras MEFs and bcl2-expressing lymphomas (Figs.
4B and 5A). Importantly, PUMA shRNAs were as potent as a p53
shRNA in promoting lymphomagenesis (Fig. 4A) (16). More-
over, myc was required for these effects because only one-sixth
of mice reconstituted with WT HSCs expressing PUMA shRNAs
formed a lymphoma of T cell origin. Therefore, like p53 loss,
PUMA suppression can potently cooperate with myc during
lymphomagenesis.
shPUMA Lymphomas Are Aggressive Pre-B Cell Lymphomas That
Retain p53-Dependent Cell-Cycle Checkpoints. To further character-
ize tumorigenesis produced by PUMA suppression, we moni-
tored lymphoma manifestation in recipient animals and con-
ducted a variety of pathological analyses. In agreement with the
survival data, whole-body fluorescence imaging of GFP expres-
sion in developing lymphomas revealed that the onset and
overall distribution of shPUMA lymphomas closely resembled
that occurring in shp53 lymphomas. Specifically, as was shown
for E-myc shp53 tumors in ref. 16, E-myc shPUMA lympho-
mas typically involved many of the peripheral lymph nodes,
including cervical, inguinal, brachial, and mesenteric lymphomas
(Fig. 5A) (data not shown), with significant dissemination into
the liver and spleen (Fig. 5B) (data not shown). Consistent with
previous studies on p53-null lymphomas, both shPUMA and
shp53 lymphomas rarely displayed the ‘‘starry sky’’ histology
Fig. 3. PUMA loss transforms E1Aras MEFs but not ras-transduced MEFs. (A)
E1Aras or ras MEFs coexpressing a control vector, PUMA shRNAs, or a p53
shRNA were injected s.c. into athymic nude mice and monitored for tumor
formation. Shown is the number of tumors per injected site. The tumor
incidence from p53/ MEFs expressing E1Aras or ras is also displayed. (B)
Relative growth rate of s.c. tumors induced by MSCV-, shPU-3-, and shp53-
infected E1Aras MEFs. (C) GFP imaging of tumors arising from ras and E1Aras
MEFs transduced with PUMA and p53 shRNAs.
Fig. 4. Acceleration of myc-induced lymphomagenesis by PUMA shRNAs. (A)
Mice reconstituted with stem cells infected with the indicated PUMA shRNAs
were monitored for tumor onset and illness until they reached a terminal
stage and were killed. The data are presented in a Kaplan–Meier format
showing the percentage of mouse survival at various times postreconstitution.
The shp53 survival data represents an updated cohort of mice, including
previously published shp53-recipient mice (16). (B) Western blot of shPUMA-
induced tumors showing decreased levels of PUMA relative to control E-myc
bcl2 lymphomas and MEFs infected with E1Aras. Tubulin is shown as a
loading control.
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indicative of the extensive apoptosis observed in E-myc lym-
phomas (Fig. 5B) (6), and both were classified as pre-B cell
lymphomas by immunophenotyping (Fig. 5C). Thus, the effects
of p53 loss and PUMA suppression on myc-induced lym-
phomagenesis are strikingly similar.
The data described above suggest that disruption of apoptosis
through PUMA suppression can mimic p53 loss during myc-
induced lymphomagenesis. To determine whether shPUMA
lymphomas have acquired defects in p53-dependent arrest func-
tions, we examined the integrity of the radiation-induced cell-
cycle checkpoint in shPUMA lymphomas. Tumor-bearing mice
were subjected to whole body -irradiation, and, 36 h later, the
lymphomas were harvested and subjected to DNA content
analysis by using flow cytometry. In contrast to p53/ lympho-
mas but comparable with control and Bcl2-expressing lympho-
mas with intact p53 (8), shPUMA lymphomas accumulated in G1
and showed a significant reduction in S phase after irradiation
(Fig. 5D) (data not shown), implying that the effects of PUMA
shRNAs on tumorigenesis do not require secondary mutations
that compromise p53-dependent cell-cycle checkpoints. Inter-
estingly, unirradiated p53-deficient lymphomas displayed a sub-
stantially increased S-phase population relative to shPUMA
lymphomas at the time of isolation (data not shown). Therefore,
although the increased proliferative rate associated with p53
mutations may confer advantages over PUMA suppression at
later stages of tumor evolution, our data indicate that loss of
apoptosis through PUMA disruption phenocopies p53 loss in
promoting E-myc lymphomagenesis.
Discussion
Our studies indicate that suppression of PUMA can approximate
the effects of p53 loss during E1Aras-mediated transformation
of primary MEFs and during Myc-induced lymphomagenesis. As
such, they demonstrate that PUMA is an important component
of the p53 tumor suppressor network and highlight the utility of
stable RNAi technology to evaluate the activity of candidate
tumor-suppressor genes.
These results demonstrate that PUMA can function as a bona
fide tumor suppressor in mice. The effects of PUMA suppression
were equivalent to p53 loss in promoting lymphoma onset and
were nearly as effective as p53 loss during E1Aras-induced
transformation. Although mutations in BH3-only proteins have
yet to be identified in human tumor specimens, our work predicts
that PUMA suppression, through loss of p53 transactivating
functions or direct mutations, may contribute to human cancer.
Interestingly, PUMA maps to chromosome 19q13.3, which is
altered in human gliomas, neuroblastomas, and B cell lympho-
mas (29–31). Notably, complete inactivation of PUMA may not
be necessary to promote tumor phenotypes because, although
PUMA expression was substantially reduced in shPUMA-
expressing lymphomas, it was still detectable (Fig. 4B).
Interestingly, PUMA-null mice are not overtly tumor-prone
(14, 15). Although, at first glance, these results are contradictory
to our findings, they suggest that the ability of PUMA to mediate
apoptosis and tumor suppression is context-dependent. In fact,
our studies demonstrate that the ability of PUMA to act as a
tumor suppressor can be dependent on other oncogenic events.
Hence, although PUMA shRNAs cooperated effectively with
E1Aras and myc to promote tumorigenesis in vivo, they did not
cooperate with ras alone. By analogy, bcl2, a PUMA antagonist,
efficiently cooperates with myc during lymphomagenesis but is
not a potent oncogene on its own.
Our study has important implications for understanding p53
action in tumor suppression. We previously showed that bcl2
overexpression could mimic p53 loss during myc-induced lym-
phomagenesis and suggested that disruption of apoptosis was
sufficient to explain the tumorigenic advantage conferred by p53
mutations in this context. Here, we show that PUMA, a p53
effector that promotes apoptosis but not cell-cycle arrest, can
account for p53 action in at least some settings where p53 acts
as a tumor suppressor. These data reinforce the notion that,
despite the diversity of p53 activities, its action in tumor sup-
pression can be mediated by only one effector function. Conse-
quently, although p53-null lymphomas may have many defects,
our data imply that some are byproducts of tumorigenesis and do
not provide any immediate advantage to the developing tumor.
Fig. 5. shPUMA lymphomas phenocopy shp53 lymphomas. (A) In vivo GFP
imaging showing cervical lymphomas in mice reconstituted with E-myc HSCs
transduced with PUMA and p53 shRNAs. (B) Hematoxylineosin staining of
shPUMA lymphoma and liver sections, showing an absence of apoptotic cell
clusters and perivascular and perenchymal infiltration of tumor cells, respec-
tively. (C) Immunophenotyping of shPUMA and shp53 tumors by flow cytom-
etry reveals that both tumors are pre-B cell lymphomas. Unlike the shPUMA
vector, the shp53 vector lacks GFP expression. Thus, the resulting tumors are
GFP-negative. (D) Mice harboring shPUMA and p53/ lymphomas were left
untreated or irradiated at 6 Gy, and DNA content analysis was performed on
extracted lymphoma cells 36 h later. The relative ratios of the percent of
irradiated vs. nonirradiated shPUMA and p53/ lymphoma cells in each
cell-cycle stage are shown.






Importantly, PUMA does not approximate p53 action in
modulating all tumor phenotypes. Whereas p53 loss is an effec-
tive initiator of T cell lymphomagenesis (7), PUMA suppression
is not, based on our results and the findings in refs. 14 and 15.
Additionally, although p53 and PUMA shRNAs transformed
primary MEFs with E1Aras, only p53 shRNAs or p53 deletions
cooperated with ras-induced transformation. This context de-
pendence can be understood in light of the underlying p53
biology. The E1A and myc oncogenes induce proliferation but
also activate p53 to promote apoptosis (26, 32, 33). Hence,
disruption of the p53-dependent apoptotic activity provides an
immediate and potent advantage to the oncogene-expressing
cells but provides little benefit to proliferation-restricted normal
cells not subject to an apoptotic stimulus. In contrast, oncogenic
ras promotes proliferation but also activates p53 to promote
cellular senescence (20). Here, p53’s arrest functions may be
crucial for its tumor suppressor activity. Because PUMA does
not mediate these functions, its inactivation does not mimic p53
loss in this setting. The differential relevance of apoptosis in
p53-mediated tumor suppression also may explain why certain
p53 mutants, defective in apoptosis but not cell-cycle arrest, are
impaired in their ability to initiate T cell lymphomagenesis (10).
In summary, our results imply that the p53 functions under-
lying its tumor-suppressor activity are context-dependent and
may be influenced by cell type, microenvironment, and onco-
genic events acquired during the course of tumor evolution. In
some settings, such as in E1Aras transformation and myc-
induced lymphomagenesis, disruption of apoptosis by PUMA
loss or defects in other apoptotic regulators is sufficient to
promote tumorigenesis, whereas defects in cell-cycle check-
points and genomic instability are apparently byproducts of p53
loss. However, these byproducts may provide new capabilities
that become relevant later during tumor progression or cancer
therapy, producing tumors that are more aggressive than those
acquiring strictly antiapoptotic lesions (17). It is noteworthy that
p53-deficient lymphomas, once established, progress to a lethal
stage more rapidly than those expressing PUMA shRNAs,
perhaps because of their higher proliferative capacity or in-
creased genomic instability (data not shown). Undoubtedly, in
other settings, defects in cell-cycle checkpoints provide the
driving force for p53 mutations, with apoptotic defects being
byproducts of p53 loss. Because essential p53 tumor-suppressor
functions are context-dependent, effective strategies to treat p53
mutant tumors also may depend on context. Understanding
which p53 function(s) are key to the evolution of different tumor
types may ultimately identify activities required for tumor main-
tenance and suggest targets for therapeutic intervention.
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